Bosutinib is a potent, ATP-competitive Src/Abl kinase inhibitor. It affects BCR-ABL and Src signaling pathways by competing with ATP to inhibit kinase phosphorylation, effectively suppressing cancer cell proliferation and inducing apoptosis.
SKI-606 (Bosutinib) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for SKI-606 (Bosutinib) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.
Jump to
- SKI-606 (Bosutinib) Mechanism of Action: BCR-Abl Inhibition in Leukemia Cell Research
- SKI-606 (Bosutinib) Clinical Trials
- SKI-606 (Bosutinib) Working Concentration | Cell Culture | Treatment
- SKI-606 (Bosutinib) Solubility in DMSO
- SKI-606 (Bosutinib) Stock Solution
- SKI-606 (Bosutinib) Storage
- SKI-606 (Bosutinib) Stability
- SKI-606 (Bosutinib) Combination Database
- SKI-606 (Bosutinib) Molecular Weight
- SKI-606 (Bosutinib) SMILES
- SKI-606 (Bosutinib) CAS Number
- SKI-606 (Bosutinib) Chemical Structure (2D and 3D)
- SKI-606 (Bosutinib) Sigma (1076180)? Try a better option.
- SKI-606 (Bosutinib) APExBIO (A2149)? Try a better option.
- SKI-606 (Bosutinib) Cayman (12030)? Try a better option.
- SKI-606 (Bosutinib) MedChemExpress (HY-10158)? Try a better option.
- SKI-606 (Bosutinib) SDS｜MSDS